South Korea $48 Billion Pharmaceutical Company Samsung Biologics to Buy Switzerland Peptide Contract Manufacturer PolyPeptide Group for $1.8 Billion (CHF 1.46 Billion) in All-Cash Deal Representing +40% Premium to Unaffected Closing Price (10/4/26), PolyPeptide Group Founded in 1952, PolyPeptide Group Current Market Value at $1.7 Billion, Share Price +67.6% YTD, +94% Last 12 Months & -59.8% Last 5 Years
24th July 2026 | Hong Kong
South Korea pharmaceutical company Samsung Biologics ($48 billion market value) has announced to buy Switzerland peptide contract manufacturer PolyPeptide Group ($1.7 billion market value) for $1.8 billion (CHF 1.46 billion) in all-cash deal, representing +40% premium to PolyPeptide Group unaffected closing price (10/4/26). PolyPeptide Group was founded in 1952. PolyPeptide Group current market value at $1.7 billion, share price +67.6% YTD, +94% last 12 months & -59.8% last 5 years. Samsung Biologics – Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. PolyPeptide Group – PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India.
“ South Korea $48 Billion Pharmaceutical Company Samsung Biologics to Buy Switzerland Peptide Contract Manufacturer PolyPeptide Group for $1.8 Billion (CHF 1.46 Billion) in All-Cash Deal Representing +40% Premium to Unaffected Closing Price (10/4/26), PolyPeptide Group Founded in 1952, PolyPeptide Group Current Market Value at $1.7 Billion, Share Price +67.6% YTD, +94% Last 12 Months & -59.8% Last 5 Years “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
South Korea $48 Billion Pharmaceutical Company Samsung Biologics to Buy Switzerland Peptide Contract Manufacturer PolyPeptide Group for $1.8 Billion (CHF 1.46 Billion) in All-Cash Deal Representing +40% Premium to Unaffected Closing Price (10/4/26), PolyPeptide Group Founded in 1952, PolyPeptide Group Current Market Value at $1.7 Billion, Share Price +67.6% YTD, +94% Last 12 Months & -59.8% Last 5 Years
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
